000165513 001__ 165513
000165513 005__ 20240403113221.0
000165513 0247_ $$2doi$$a10.1007/s12311-022-01484-3
000165513 0247_ $$2pmid$$apmid:36208403
000165513 0247_ $$2ISSN$$a1473-4222
000165513 0247_ $$2ISSN$$a1473-4230
000165513 0247_ $$2altmetric$$aaltmetric:136936544
000165513 037__ $$aDZNE-2022-01661
000165513 041__ $$aEnglish
000165513 082__ $$a610
000165513 1001_ $$aBourcier, Dax$$b0
000165513 245__ $$aFrench Translation and Cross-cultural Adaptation of the Scale for the Assessment and Rating of Ataxia.
000165513 260__ $$aLondon$$bDunitz$$c2023
000165513 3367_ $$2DRIVER$$aarticle
000165513 3367_ $$2DataCite$$aOutput Types/Journal article
000165513 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1700493504_2202
000165513 3367_ $$2BibTeX$$aARTICLE
000165513 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000165513 3367_ $$00$$2EndNote$$aJournal Article
000165513 520__ $$aThe Scale for the Assessment and Rating of Ataxia (SARA) is a widely used scale for assessing the severity of ataxia in clinics, natural history studies, and treatment trials worldwide. However, no French translation with validated cross-cultural adaptation is available. This study aimed to translate and adapt the SARA into French. The translation process was conducted according to the ISPOR guidelines for the translation and cultural adaptation process for patient-reported outcomes. A total of five translators, an expert committee, and two physiotherapists took part in the process to assess and ensure comprehension and language equivalences of the final French version. A few misinterpretations were pointed out during the translation process and were changed accordingly by the translation team. The French version of the SARA is ready to be used in clinical and research settings with French-speaking populations living with ataxia.
000165513 536__ $$0G:(DE-HGF)POF4-353$$a353 - Clinical and Health Care Research (POF4-353)$$cPOF4-353$$fPOF IV$$x0
000165513 588__ $$aDataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
000165513 650_7 $$2Other$$aAtaxia
000165513 650_7 $$2Other$$aCross-cultural adaptation
000165513 650_7 $$2Other$$aISPOR guidelines
000165513 650_7 $$2Other$$aPsychometric properties
000165513 650_7 $$2Other$$aTranslation
000165513 650_2 $$2MeSH$$aHumans
000165513 650_2 $$2MeSH$$aCross-Cultural Comparison
000165513 650_2 $$2MeSH$$aSurveys and Questionnaires
000165513 650_2 $$2MeSH$$aReproducibility of Results
000165513 650_2 $$2MeSH$$aPsychometrics
000165513 650_2 $$2MeSH$$aLanguage
000165513 650_2 $$2MeSH$$aCerebellar Ataxia
000165513 7001_ $$aBélair, Nicolas$$b1
000165513 7001_ $$aPedneault-Tremblay, Élyse-Anne$$b2
000165513 7001_ $$aLessard, Isabelle$$b3
000165513 7001_ $$0P:(DE-2719)2810314$$aKlockgether, Thomas$$b4$$udzne
000165513 7001_ $$0P:(DE-2719)2811275$$aSynofzik, Matthis$$b5$$udzne
000165513 7001_ $$aRahn, Caroline$$b6
000165513 7001_ $$aBrais, Bernard$$b7
000165513 7001_ $$aDuchesne, Elise$$b8
000165513 7001_ $$00000-0003-2829-8470$$aGagnon, Cynthia$$b9$$eCorresponding author
000165513 773__ $$0PERI:(DE-600)2071266-2$$a10.1007/s12311-022-01484-3$$n6$$p1118 - 1122$$tThe Cerebellum$$v22$$x1473-4222$$y2023
000165513 8564_ $$uhttps://link.springer.com/article/10.1007/s12311-022-01484-3
000165513 8564_ $$uhttps://pub.dzne.de/record/165513/files/DZNE-2022-01661_Restricted.pdf
000165513 8564_ $$uhttps://pub.dzne.de/record/165513/files/DZNE-2022-01661_Restricted.pdf?subformat=pdfa$$xpdfa
000165513 909CO $$ooai:pub.dzne.de:165513$$pVDB
000165513 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2810314$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b4$$kDZNE
000165513 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2811275$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b5$$kDZNE
000165513 9131_ $$0G:(DE-HGF)POF4-353$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vClinical and Health Care Research$$x0
000165513 9141_ $$y2023
000165513 915__ $$0StatID:(DE-HGF)3002$$2StatID$$aDEAL Springer$$d2021-02-02$$wger
000165513 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2021-02-02
000165513 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2021-02-02
000165513 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-08-24
000165513 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-08-24
000165513 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-08-24
000165513 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-08-24
000165513 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bCEREBELLUM : 2022$$d2023-08-24
000165513 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2023-08-24
000165513 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2023-08-24
000165513 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2023-08-24
000165513 9201_ $$0I:(DE-2719)1011001$$kAG Klockgether$$lPatient Studies$$x0
000165513 9201_ $$0I:(DE-2719)5000063$$kAG Synofzik$$lSystems Neurodegeneration$$x1
000165513 980__ $$ajournal
000165513 980__ $$aVDB
000165513 980__ $$aI:(DE-2719)1011001
000165513 980__ $$aI:(DE-2719)5000063
000165513 980__ $$aUNRESTRICTED